Your Health, We Care
Abrotinib, as a selective inhibitor of Janus kinase 1 (JAK1), has been widely studied for the treatment of moderate to severe atopic dermatitis.
Abrocetinib was compared head to head with dabigatran in a phase III clinical study, and the results showed that in multiple efficacy measures, Abrocetinib was statistically superior.
Focusing on the multi-version characteristics of this drug, patients and medical···【more】
Release date：2025-05-14Recommended：92
Focusing on the multi-version characteristics of this drug, patients and medical···【more】
Release date：2025-05-13Recommended：117
An innovative drug has attracted widespread attention in the medical field in re···【more】
Release date：2025-05-13Recommended：128
